RTP Mobile Logo
Head and Neck Cancer Update, Issue 1, 2017
Released October 2017

Proceedings from video interviews with Drs Robert I Haddad and Francis Paul Worden on optimal strategies and emerging concepts in the management of head and neck and thyroid cancers. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists and other healthcare providers involved in the treatment of head and neck and thyroid cancers.

    Head and neck cancers account for approximately 3% of all cancers in the United States. Treatment for patients with head and neck cancer is complex and requires a multidisciplinary team of individuals with specialized expertise. Thyroid cancer is one of the most rapidly increasing cancers in the United States with an estimated 56,870 new cases expected to be diagnosed in 2017. Most patients with thyroid cancer can be cured with local treatments and radioactive iodine. Medical oncology intervention typically only occurs for those patients with progressive metastatic disease.

    Published results from ongoing trials lead to the continuing emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. This program uses one-on-one discussion with leading oncology investigators about treatment controversies and the integration of key data sets into the practical management of cancers of the head, neck and thyroid.


    • Counsel patients with HPV-positive squamous cell carcinoma of the head and neck (SCCHN) about the contribution of the virus to the etiology and prognosis of their disease, and consider this information as part of protocol and nonresearch treatment planning.
    • Appreciate available safety and efficacy data with the use of cetuximab alone or in combination with other local or systemic therapies, and appropriately integrate this agent into the management of locally advanced, recurrent or metastatic SCCHN.
    • Appraise the rationale for and clinical data with investigational anti-PD-1/PD-L1 antibodies in patients with SCCHN, and use this information to counsel appropriate individuals regarding clinical trial opportunities or expanded access programs with these agents.
    • Communicate the benefits and risks of approved targeted biologic therapies to patients with metastatic thyroid cancer (TC), and develop an evidence-based algorithm to sequence available options based on disease- and patient-specific characteristics.
    • Appreciate the recent FDA approval of lenvatinib for metastatic differentiated TC, and discern how this agent can be optimally integrated into clinical practice.
    • Recognize the roles of cabozantinib and vandetanib in the management of metastatic medullary TC, and ensure appropriate supportive care measures to minimize the side effects associated with these agents.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Robert I Haddad, MD
    Disease Center Leader
    Center for Head and Neck Oncology
    Dana-Farber Cancer Institute
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Merck, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Pfizer Inc. 

    Francis Paul Worden, MD
    Associate Professor
    University of Michigan
    Comprehensive Cancer Center
    Ann Arbor, Michigan

    Advisory Committee: Bristol-Myers Squibb Company, Genzyme Corporation, Merck; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Galera Therapeutics Inc, Merck, Pfizer Inc. 

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Eisai Inc, Lilly and Merck.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2017
    Expiration date: October 2018

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Interview with Robert I Haddad, MD

Interview with Francis Paul Worden, MD

Select Publications